Headlands Technologies LLC Increases Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• Headlands Technologies LLC increased its holdings in Thermo Fisher Scientific Inc. by 27.0% during the first quarter, bringing their total shares to 6,233, valued at $3.1 million.
• Thermo Fisher Scientific reported earnings of $5.36 per share for the latest quarter, exceeding analysts' expectations of $5.22, with a revenue of $10.86 billion.
• The company announced a quarterly dividend of $0.43 per share, set to be paid on October 15th, reflecting a dividend yield of 0.4%.

Headlands Technologies LLC lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 27.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,233 shares of the medical research company's stock after purchasing an additional 1,324 shares during the period. Headlands Technologies LLC's holdings in Thermo Fisher Scientific were worth $3,102,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of TMO. Bernard Wealth Management Corp. acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $25,000. Ameriflex Group Inc. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth approximately $30,000. IMA Advisory Services Inc. purchased a new stake in Thermo Fisher Scientific in the first quarter valued at approximately $35,000. Navigoe LLC acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at $37,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Down 3.6%

NYSE:TMO opened at $449.68 on Thursday. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The stock has a fifty day simple moving average of $424.58 and a 200-day simple moving average of $465.66. The company has a market capitalization of $169.80 billion, a PE ratio of 26.01, a price-to-earnings-growth ratio of 2.49 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter in the previous year, the business posted $5.37 earnings per share. The firm's quarterly revenue was up 2.9% compared to the same quarter last year. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective on the stock in a research report on Friday, July 11th. Wells Fargo & Company lowered their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. Argus decreased their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research report on Tuesday, April 29th. HSBC reissued a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, UBS Group increased their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday, July 24th. Six research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $593.00.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.